Murphy Capital Management’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | $2.56M | Sell |
21,744
-225
| -1% | -$26.7K | 0.36% | 63 |
|
|
2022
Q1 | $2.86M | Sell |
21,969
-1,774
| -7% | -$231K | 0.33% | 67 |
|
|
2021
Q4 | $3.62M | Sell |
23,743
-347
| -1% | -$53.7K | 0.39% | 58 |
|
|
2021
Q3 | $3.89M | Sell |
24,090
-297
| -1% | -$50K | 0.46% | 53 |
|
|
2021
Q2 | $3.99M | Sell |
24,387
-42
| -0.2% | -$6.47K | 0.46% | 53 |
|
|
2021
Q1 | $3.68M | Buy |
24,429
+1,133
| +5% | +$180K | 0.46% | 53 |
|
|
2020
Q4 | $3.53M | Buy |
23,296
+620
| +3% | +$88.6K | 0.47% | 53 |
|
|
2020
Q3 | $3.07M | Sell |
22,676
-63
| -0.3% | -$8.55K | 0.45% | 56 |
|
|
2020
Q2 | $3.11M | Sell |
22,739
-25
| -0.1% | -$3.19K | 0.49% | 51 |
|
|
2020
Q1 | $2.45M | Sell |
22,764
-925
| -4% | -$106K | 0.47% | 56 |
|
|
2019
Q4 | $2.85M | Sell |
23,689
-1,070
| -4% | -$119K | 0.41% | 63 |
|
|
2019
Q3 | $2.46M | Sell |
24,759
-135
| -0.5% | -$14.1K | 0.37% | 69 |
|
|
2019
Q2 | $2.71M | Sell |
24,894
-1,111
| -4% | -$118K | 0.41% | 63 |
|
|
2019
Q1 | $2.91M | Sell |
26,005
-3,310
| -11% | -$363K | 0.44% | 59 |
|
|
2018
Q4 | $2.83M | Sell |
29,315
-875
| -3% | -$92.9K | 0.47% | 56 |
|
|
2018
Q3 | $3.68M | Buy |
30,190
+135
| +0.4% | +$15.9K | 0.51% | 55 |
|
|
2018
Q2 | $3.3M | Sell |
30,055
-340
| -1% | -$36.4K | 0.48% | 58 |
|
|
2018
Q1 | $3.24M | Sell |
30,395
-1,885
| -6% | -$209K | 0.46% | 57 |
|
|
2017
Q4 | $3.45M | Sell |
32,280
-360
| -1% | -$38.5K | 0.47% | 56 |
|
|
2017
Q3 | $3.63M | Sell |
32,640
-240
| -0.7% | -$25.7K | 0.52% | 57 |
|
|
2017
Q2 | $3.4M | Sell |
32,880
-45
| -0.1% | -$4.43K | 0.5% | 60 |
|
|
2017
Q1 | $3.22M | Hold |
32,925
| – | – | 0.48% | 61 |
|
|
2016
Q4 | $2.91M | Sell |
32,925
-786
| -2% | -$71.5K | 0.46% | 62 |
|
|
2016
Q3 | $3.25M | Sell |
33,711
-354
| -1% | -$33.7K | 0.5% | 58 |
|
|
2016
Q2 | $2.92M | Sell |
34,065
-2,835
| -8% | -$254K | 0.45% | 60 |
|
|
2016
Q1 | $3.21M | Sell |
36,900
-3,705
| -9% | -$331K | 0.5% | 58 |
|
|
2015
Q4 | $4.58M | Sell |
40,605
-840
| -2% | -$91.2K | 0.7% | 45 |
|
|
2015
Q3 | $4.19M | Sell |
41,445
-1,470
| -3% | -$176K | 0.69% | 43 |
|
|
2015
Q2 | $5.28M | Sell |
42,915
-1,740
| -4% | -$208K | 0.79% | 40 |
|
|
2015
Q1 | $5.11M | Sell |
44,655
-465
| -1% | -$51.3K | 0.75% | 41 |
|
|
2014
Q4 | $4.56M | Sell |
45,120
-3,810
| -8% | -$370K | 0.7% | 42 |
|
|
2014
Q3 | $4.46M | Sell |
48,930
-4,455
| -8% | -$391K | 0.7% | 43 |
|
|
2014
Q2 | $4.57M | Sell |
53,385
-7,551
| -12% | -$595K | 0.72% | 40 |
|
|
2014
Q1 | $4.8M | Sell |
60,936
-46,497
| -43% | -$3.87M | 0.81% | 36 |
|
|
2013
Q4 | $8.13M | Sell |
107,433
-1,380
| -1% | -$97.9K | 1.41% | 12 |
|
|
2013
Q3 | $7.6M | Sell |
108,813
-1,725
| -2% | -$113K | 1.44% | 12 |
|
|
2013
Q2 | $6.41M | Buy |
+110,538
| New | +$6.39M | 1.3% | 15 |
|
Other funds holding IBB
Murphy Capital Management's IBB Position: Q2 2022 in Review
Murphy Capital Management reduced its iShares Biotechnology ETF (IBB) stake by 1% in Q2 2022, selling an estimated $26.7K and leaving 21,744 shares worth $2.56M. The position accounts for 0.36% of the portfolio, ranked #63.
Murphy Capital Management first reported a position in IBB in Q2 2013 and has held it in 37 quarters since. The position peaked at $8.13M in Q4 2013. 858 funds tracked by Wall St. Rank hold IBB as of Q2 2022.
- Murphy Capital Management held 21,744 shares of iShares Biotechnology ETF worth $2.56M as of Q2 2022.
- Murphy Capital Management sold 225 iShares Biotechnology ETF shares in Q2 2022, an estimated $26.7K.
- iShares Biotechnology ETF made up 0.36% of Murphy Capital Management's portfolio in Q2 2022, its #63 holding.
- Murphy Capital Management first reported a position in iShares Biotechnology ETF in Q2 2013 and has held it in 37 quarters since.
- Murphy Capital Management's iShares Biotechnology ETF position peaked at $8.13M in Q4 2013.
- 858 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2022.
Based on Murphy Capital Management's 13F filing for Q2 2022, filed 13 Jul 2022.